Week in Review: Menarini and Lummy Announce Novel Drug In-Licensings for China

Menarini of Italy paid $100 million to in-license China and Asia-Pacific rights for a liver cancer treatment developed by Germany's 4SC AG; Chongqing Lummy Pharma, with help from TVM's $50 million China BioPharma Capital I fund, announced a $40 million deal to in-license greater China rights for a cancer immunotherapy platform from Argos Therapeutics of the US; Shanghai Fosun Pharma raised $940 million in a private placement from eight institutional investors; Guided Therapeutics of the US signed an MOU for China distribution rights to a cervical cancer screening device; Jiangsu NHWA Pharma and its Israeli partner, D-Pharm Ltd., were approved to begin China clinical trials of their epilepsy treatment; PerkinElmer was granted CFDA approval to market a new prenatal/neo-natal genetic analyzing device; and Boston Scientific enlisted Suzhou's Frankenman Medical Equipment Company to provide training to China physicians in the use of BSX's endoscopic surgery devices. More details.... Stock Symbols: (F: VSC) (SHZ: 300006) (NSDQ: ARGS) (SHA: 600196; HK: 02196) (OTCBB: GTHP; OTCQB: GTHP) (SHE: 2262) (TASE: DPRM) (NYSE: PKI) (NYSE: BSX) Share this with colleagues: // //